Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular disease, todayannounced that an abstract on the preclinical drug candidate, novel IP receptor agonist CS585 has been accepted and will be presented at the EHA 2024 Hybrid Congress, in Madrid, June 13-16, 2024.

The abstract titled "Superior Selectivity of CS585 to The Prostacyclin Receptor Translates to A New Viable Target for Prevention of Thrombosis", was authored by L. Stanger, P Yalavarthi, A. Rickenberg, K. Goerger, D. Gilmore and M. Holinstat, at University of Michigan, Ann Arbor, USA; and B. Dahlöf, Cereno Scientific, Gothenburg, Sweden.

The abstract will be presented by Livia Stanger, Graduate student at the Holinstat Lab at University of Michigan, led by Dr. Michael Holinstat, Professor in the Department of Pharmacology, the Department of Internal Medicine (Division of Cardiovascular Medicine), and the Department of Vascular Surgery at the University of Michigan. Dr. Holinstat leads Cereno's development programs at the University of Michigan and Director of Translational Research at Cereno.

Presentation Date: Saturday, 15 June, 11:45 - 12:00 CEST

Part of Session: Prevention and treatment of venous thrombosis

About CS585

CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The drug candidate CS585 has not yet been assigned a specific indication for clinical development as evaluation in the preclinical program is still ongoing.

In April 2023 Cereno announced that the Company signed a license agreement for the drug candidate CS585 with the University of Michigan. The agreement provides Cereno the exclusive rights to CS585 for further clinical development and commercialization.

In early November 2023, CS585 was highlighted by top-tier medical journal Blood as a promising novel anti-thrombotic strategy without risk of bleeding.

 

For further information, please contact:

Henrik Westdahl, Director IR & Communications

Email: [e-mail]

Phone: [phone]

 

Sten R. Sörensen, CEO

Email: [e-mail]

Phone: [phone]

 

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for rare and common cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA's Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator - regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. In April 2024, Cereno submitted a Clinical Trial Application (CTA) for a Phase I First-in-Human-Study, expected to start during Q2 2024. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.

 

https://news.cision.com/cereno-scientific/r/cereno-scientific-to-present-preclinical-data-for-drug-candidate-cs585-at-the-eha-2024-hybrid-congre,c3981721

https://mb.cision.com/Main/14131/3981721/2797784.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English